Efficacy and Safety of a Magnesium Sulfate–Rich Natural Mineral Water for Patients With Functional Constipation  Christophe Dupont, Alain Campagne, Florence Constant  Clinical Gastroenterology and Hepatology  Volume 12, Issue 8, Pages 1280-1287 (August 2014) DOI: 10.1016/j.cgh.2013.12.005 Copyright © 2014 AGA Institute Terms and Conditions

Figure 1 Flow chart of the patients. Clinical Gastroenterology and Hepatology 2014 12, 1280-1287DOI: (10.1016/j.cgh.2013.12.005) Copyright © 2014 AGA Institute Terms and Conditions

Figure 2 (A) Proportion of responders in each group and at each evaluation period (FAS population) (B) according to the Mg2+ and SO42- osmolarity of the treatment at each evaluation period (FAS population). Clinical Gastroenterology and Hepatology 2014 12, 1280-1287DOI: (10.1016/j.cgh.2013.12.005) Copyright © 2014 AGA Institute Terms and Conditions

Figure 3 Change in stool consistency from baseline to week 2 (Bristol scale, FAS population). Types I and II, hard or lumpy stool; types III through V, normal stool; types VI and VII, loose to liquid stool. *P < .05. Clinical Gastroenterology and Hepatology 2014 12, 1280-1287DOI: (10.1016/j.cgh.2013.12.005) Copyright © 2014 AGA Institute Terms and Conditions

Figure 4 Evolution of the Rome III score according to the baseline level of abdominal pain (VAS scale, 0–100 mm) (FAS population). Clinical Gastroenterology and Hepatology 2014 12, 1280-1287DOI: (10.1016/j.cgh.2013.12.005) Copyright © 2014 AGA Institute Terms and Conditions

Figure 5 Use of rescue medication (ie, macrogol 4000) (FAS population). *P < .05; ***P < .001. Clinical Gastroenterology and Hepatology 2014 12, 1280-1287DOI: (10.1016/j.cgh.2013.12.005) Copyright © 2014 AGA Institute Terms and Conditions